Noninvasive management of Indian visceral leishmaniasis: Clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit

Clinical Infectious Diseases

Volumn 35, Issue 5, 2002, Pages 581-586

  Sundar, Shyam ^a   Sahu, M ^a   Mehta, H ^a   Gupta, A ^a   Kohli, U ^a   Rai, M ^a   Berman, J D ^b   Murray, H W ^c  

^a BANARAS HINDU UNIVERSITY   (India)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIGEN; ANTIMALARIAL AGENT; IMMUNOGLOBULIN G ANTIBODY; K39 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FEMALE; FEVER; HUMAN; INDIA; LEISHMANIASIS; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SPLENOMEGALY; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; ANTIBODIES; ANTIGENS, PROTOZOAN; BIOLOGICAL MARKERS; DIAGNOSTIC TECHNIQUES AND PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; MALE; PROTOZOAN PROTEINS; RESEARCH; TREATMENT OUTCOME;

EID: 0036720443     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/342057     Document Type: Article

References (29)

1. Epidemiology, of visceral leishmaniasis in India
2. Leishmaniasis in Sudan: Visceral leishmaniasis
3. Comparative merits of sternum, spleen and liver punctures in the study of human leishmaniasis
4. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis
5. Visceral leishmaniasis in Malta - An 18 year paediatric, population based study
6. Clinical spectrum of leishmaniasis
7. Use of the recombinant K39 dipstick test and the direct agglutination test in a setting endemic for visceral leishmaniasis in Nepal
8. Comparison of microscopy and culture in the detection of Leishmania donovani from splenic aspirates
9. Use of the polymerase chain reaction to assess the success of visceral leishmaniasis treatment
10. Serodiagnosis of Indian kala-azar: Evaluation of IFA, ELISA and CIEP tests
11. Kala-azar: A comparative study of parasitological methods and the direct agglutination test in diagnosis
12. Evaluation of the direct agglutination test as an immunodiagnostic tool for kala-azar in India
13. Diagnosis of symptomatic visceral leishmaniasis by use of the polymerase chain reaction on patient blood
14. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis
15. Epidemic visceral leishmaniaisis in southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited resources
16. Clinical and experimental advances in treatment in visceral leishmaniasis
17. Serodiagnosis of Asian leishmaniasis with a recombinant antigen from the repetitive domain of Leishmania chagasi
18. Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis
19. rK39: A cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis
20. Diagnosing visceral leishmaniasis with the recombinant K39 strip test: Experience from the Sudan
21. Enzyme-linked immunosorbent assay for recombiant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis
22. Rapid accurate field diagnosis of Indian visceral leishmaniasis
23. A simple and sensitive test for field diagnosis of post kala-azar dermal leishmaniasis
24. Immunochromatographic strip-test detection of anti-K39 antibody in Indian visceral leishmaniasis
25. Drug resistance in Indian visceral leishmaniasis
26. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: Randomised trial
27. Leishmania and human immunodeficiency virus coinfection: The first 10 years
28. A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic marker for monitoring patients undergoing drug therapy